Printer Friendly

U.S. BIOSCIENCE AND SMITHKLINE BEECHAM FORM ALLIANCE IN JAPAN, SOUTH KOREA AND TAIWAN

 U.S. BIOSCIENCE AND SMITHKLINE BEECHAM
 FORM ALLIANCE IN JAPAN, SOUTH KOREA AND TAIWAN
 WEST CONSHOHOCKEN, Pa., May 5 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS) and SmithKline Beecham, plc, today announced that they have signed an agreement to form an alliance in Japan, South Korea and Taiwan to develop and market products for use in the treatment of cancer.
 Under the agreement, SmithKline Beecham will develop and market three U.S. Bioscience compounds in the territory: Ethyol(R) and WR- 151327 -- agents that protect normal tissue from some of the side effects associated with chemotherapy and radiation therapy; and PALA, a biochemical modulator that enhances the activity of certain chemotherapeutic agents. SmithKline Beecham will have exclusive marketing rights for Ethyol, and will co-market the remaining products with U.S. Bioscience in Japan. U.S. Bioscience will be responsible for manufacturing the products. In addition, the agreement includes provisions for SmithKline Beecham to assist U.S. Bioscience in establishing a marketing organization based in Japan.
 "This agreement not only provides U.S. Bioscience with a means of developing and marketing our products in Japan, but also provides a potential base from which the company can establish its own presence in this important market," said Philip S. Schein, M.D., U.S. Bioscience's chairman and chief executive officer.
 "Japan continues to be an important market for us," said Jan Leschly, chairman of SmithKline Beecham Pharmaceuticals. "These compounds have the potential to expand our business and to enhance our oncology business, which will be based on the launch of Kytril(R) -- our antiemetic for use with cancer therapies.
 U.S. Bioscience, based in West Conshohocken, is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
 SmithKline Beecham, one of the world's leading health care companies, discovers, develops, manufactures and markets human and animal pharmaceuticals, biologicals, over-the-counter medicines, health related consumer brands and clinical laboratory testing services. The company markets its more than 300 products in over 130 countries.
 -0- 5/5/92
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503/
 (UBS SBH) CO: U.S. Bioscience Inc. ST: Pennsylvania IN: MTC SU:


MM-MC -- SJ002 -- 6366 05/05/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:377
Previous Article:UNITED HEALTHCARE REPORTS FIRST QUARTER RESULTS: EARNINGS UP 61 PERCENT IN 14TH CONSECUTIVE RECORD QUARTER
Next Article:SILICON GRAPHICS EXPANDS BOB BISHOP'S ROLE IN WORLDWIDE TRADE OPERATIONS


Related Articles
BRITISH BIO-TECHNOLOGY AND SMITHKLINE BEECHAM SIGN AGREEMENT FOR RESEARCH COLLABORATION
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
SMITHKLINE BEECHAM AND COASTAL HEALTHCARE GROUP FORM STRATEGIC ALLIANCE
SMITHKLINE BEECHAM AND GIST-BROCADES AGREE TO FORM PENICILLIN MANUFACTURING ALLIANCE
SmithKline Beecham and LG Chemical Ltd Sign Agreement For New Quinolone Antibiotic
SmithKline Beecham and Kissei Pharmaceuticals in Agreement for New Cardiovascular Compound
SmithKline Beecham Appoints Dr. David C. U'Prichard Chairman, Research And Development, Pharmaceuticals
Adolor Corporation and SmithKline Beecham Execute License Agreement.
SmithKline Beecham and Asahi Chemical Sign Agreement For Obesity and Diabetes Compounds.
Tularik Announces the Appointment of James Huang to Vice President of Business Development and Commercial Operations.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters